Abstract Number: PB0377
Meeting: ISTH 2021 Congress
Background: Pediatric chronic kidney diseases (CDK) are mainly associated with kidneys congenital anomalies or urinary and glomerular tract diseases. IL-33 (or IL-1F11) is a cytokine with pro-inflammatory or regulatory roles, depending on the pathological context. CXCL-16 (CXC motif ligand 16) may function as chemoattractant of activated T cells, as an adhesion molecule, or as a scavenger receptor. Both, IL-33, CXCL-16 may have a dual role in the inflammatory response. IL-17 is a pro-inflammatory cytokine. Understanding the effects of cytokines on the onset and progression of pediatric CDK is crucial as new prognostic markers and maybe as alternative therapeutic targets.
Aims: Evaluating IL-33, CXCL16 and IL-17 plasma levels in CKD pediatric patients and healthy volunteers (control group).
Methods: This study was previously approved by the local Ethical Committee of The Federal University of Minas Gerais (# 07513513.9.0000.5149) and consent was obtained in all cases. It included 38 CKD pediatric patients (6-18 years old) and 31 healthy volunteers matching age and sex. IL-33, CXCL16 and IL-17 plasma levels were determined by immunoassays.
Results: Median and interquartile range for IL-33 were 205.8 pg/mL (225.1) in CDK group and 334.42 pg/mL (261.53) in controls (P=0,027), for CXCL-16, 168.44 pg/mL (112.3) in CKD group and 260.68 pg/mL (213.56) in controls (P≤0,001) and for IL-17, 14.91 pg/mL(16.34) in CKD group and 55.04 pg/mL (45.87) in controls (P≤0,001).
Table 1 show the statistical results of the cytokines.
|Parameters||CKD group||Control group||P value|
|IL-33 pg/mL||205.8 (225.1)||334.42 (261.53)||0.027|
|CXCL-16 pg/mL||168.44 (112.3)||260.68 (213.56)||0.001|
|IL-17 pg/mL||14.91 (16.34)||55.04 (45.87)||0.001|
Conclusions: Kidney diseases are complex and heterogeneous. Our findings suggest a compromised regulation of inflammatory process in CKD pediatric patients. However other studies are need to clarify how the citokynes are involved in the disease pathogenesis and mainly the CKD progress.
To cite this abstract in AMA style:Silva A, Perucci L, Silva R, Sousa L, Talvani A, Mota AP, Dusse L, Alpoim P. Immune Mediators in Pediatric Patients with Chronic Kidney Disease [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 1). https://abstracts.isth.org/abstract/immune-mediators-in-pediatric-patients-with-chronic-kidney-disease/. Accessed September 16, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/immune-mediators-in-pediatric-patients-with-chronic-kidney-disease/